Charlottesville, VA – InSpark Technologies, Inc., a company dedicated to providing real-time, actionable blood glucose insights to diabetes patients and clinicians, is pleased to announce that Laurel Fuqua, RN, MSN, CMC will be joining the company in the position of Sr. Vice President of Clinical Affairs, effective June 29th, 2015. At InSpark, Laurel will be responsible for leading clinician outreach, patient and clinician education, clinical study collaborations and medical affairs. She will also be supporting product development and marketing efforts.
Ms. Fuqua is an accomplished health care industry innovator with over 20 years of hands-on operational, product marketing, clinical, new business model development and executive leadership experience in chronic disease management and care coordination. She has won several awards for her work in diabetes care and health care services delivery, including being named AADE Diabetes Educator of the Year early in her career.
“We are delighted that Laurel will be joining us as we prepare for the launch of Vigilant™† and plan to more actively engage with clinical and patient stakeholders. Laurel’s wealth of experience will also help us further enhance and generate awareness of the scientific and clinical support for our pattern recognition technology,” said Erik Otto, President and Co-Founder of InSpark.
“I am very excited and honored to be joining the InSpark team,” said Ms. Fuqua. “With the launch of Vigilant™†, the company has the opportunity to make a significant difference in the lives of people living with diabetes. Today’s diabetes landscape has a growing number of solutions for data capture but there is a need for reliable patient-centered tools for analysis and use of that data. The company’s easy-to-use technology will go a long way in empowering people with diabetes to make decisions that can improve their health and wellbeing.”
About InSpark Technologies, Inc.
InSpark Technologies is developing tools that help people with diabetes transform the significant amount of blood glucose data captured on a daily basis into useful insight. InSpark’s technology alerts patients and clinicians about patterns indicative of periods of risk at the time they need it most (such as when a patient is testing, and in advance of the period of risk) rather than requiring users to extract insights from detailed charts, graphs and log books. InSpark’s technology is derived from a broad suite of pattern recognition intellectual property licensed from the University of Virginia Licensing and Ventures Group. More information can be found at www.insparktech.com.
Vigilant™† is a mobile health software solution that analyzes blood glucose data and provides feedback about daily patterns of hyperglycemia, hypoglycemia, glucose variability and test frequency, as well as patterns indicative of increased risk of severe hypoglycemia in the next 24 hours. It is designed to provide concise messages prior to periods of risk so that users can take action to improve their glucose control.
† Vigilant™ is an investigational use software device that is not currently available for sale in the United States.